Outcomes11

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 11 of 11

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Response Rate	From the start of treatment and every 8 weeks/2 cycles with a range of cycles attempted 1-15.	All patients that received one dose of nivolumab were evaluable for this objective.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Progression-free Survival (PFS)	From start of treatment and every 8 weeks/2 cycles until progressive disease or death. Median follow up of 4.5 months		Months	MEDIAN
SECONDARY	Overall Survival (OS) at 3 Months and 6 Months	At 3 months and 6 months from the initiation of treatment		percentage of patients alive	NUMBER
SECONDARY	Toxicity of Nivolumab	From treatment initiation, twice every Cycle (every 14 days) while on treatment, up to 12 weeks after final dose. Range of cycles completed 1-15 (1 Cycle=28 days)		participants	NUMBER
OTHER_PRE_SPECIFIED	Levels of Cytokines	At baseline and at 4 weeks of treatment
OTHER_PRE_SPECIFIED	Levels of Peripheral Blood Lymphocyte Phenotype	At baseline and at 4 weeks of treatment
OTHER_PRE_SPECIFIED	PD-L1 Expression	At baseline and at 4 weeks of treatment
OTHER_PRE_SPECIFIED	PD-L2 Expression	At baseline and at 4 weeks of treatment
OTHER_PRE_SPECIFIED	Peripheral T Cell Profile Levels	At baseline and at 4 weeks of treatment
OTHER_PRE_SPECIFIED	Serum Interleukin Levels	At baseline and at 4 weeks of treatment
POST_HOC	Progression Free Survival Rate at 3 Months and 6 Months	At 3 months and 6 months from the initiation of treatment		percentage of patients with PFS	NUMBER

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02720484/outcomes